Zi-Yuan Zhou‡
ab,
Jing Yuan‡a,
Qing Panc,
Xiao-Mei Moa,
Yong-Li Xiea,
Feng Yinb,
Zigang Li*b and
Nai-Kei Wong*a
aDepartment of Infectious Diseases, Shenzhen Third People's Hospital, The Second Hospital Affiliated to Southern University of Science and Technology, Shenzhen 518112, China. E-mail: wongnksz@163.com
bDepartment of Chemical Biology, School of Chemical Biology and Biotechnology, Shenzhen Graduate School of Peking University, Shenzhen 518055, China. E-mail: lizg@pkusz.edu.cn
cShenzhen Key Laboratory of Microbial Genetic Engineering, College of Life Sciences and Oceanology, Shenzhen University, Shenzhen 518055, China
First published on 25th June 2019
Antimicrobial resistance (AMR) presents as a serious threat to global public health, which urgently demands action to develop alternative antimicrobial strategies with minimized selective pressure. The bacterial SOS response regulator RecA has emerged as a promising target in the exploration of new classes of antibiotic adjuvants, as RecA has been implicated in bacterial mutagenesis and thus AMR development through its critical roles in error-prone DNA repair. The natural product curcumin has been reported to be an effective RecA inhibitor in several Gram-negative bacteria, but details on the underlying mechanisms are wanting. In order to bridge the gap in how curcumin operates as a RecA inhibitor, we used computational approaches to model interactions between RecA protein and curcumin analogues. We first identified potential binding sites on E. coli RecA protein and classified them into four major binding pockets based on biological literature and computational findings from multiple in silico calculations. In docking analysis, curcumin–thalidomide hybrids were predicted to be superior binders of RecA compared with bis-(arylmethylidene)acetone curcumin analogues, which was further confirmed by MMGBSA calculations. Overall, this work provides mechanistic insights into bacterial RecA protein as a target for curcumin-like compounds and offers a theoretical basis for rational design and development of future antibiotic adjuvants.
Considerable incentives have been put on developing new compounds that target components of the bacterial adaptive response to selective pressure induced by antibiotics themselves. Notably, the bacterial RecA protein plays pivotal roles in several key processes leading to the acquisition of antibiotic resistance, namely, SOS response, horizontal gene transfer,11 and mutagenesis.12,13 RecA is a 38 kDa DNA recombinase best known for its regulatory function in bacterial DNA repair.14 As a DNA-dependent ATPase, it requires ATP to bind ssDNA (single-stranded DNA) in order to form a nucleoprotein filament.13 Bacterial DNA recombination is key to DNA repair and genome maintenance. In this process, RecA catalyzes the central steps of DNA recombination, aligning, pairing and DNA strand exchange reaction. In addition, RecA itself critically controls the initiation of the SOS response, by triggering autocatalytic cleavage of the transcriptional repressor LexA.14,15 In the contexts of AMR development under sublethal concentrations of antibiotics, RecA hyperactivity in SOS response results in runaway expression of inducible low-fidelity DNA repair systems (e.g. the error-prone polymerase V16,17) that drive consequent mutations,18 paving the way for genomic instability and mutagenesis-driven resistance acquisition.19 Taken as a whole, RecA seems a promising target for blocking the evolution or acquisition of bacterial antibiotic resistance.
One of the alternative approaches to conventional antibiotic regimens is to reduce antibiotic dosage while enhancing its performance via the complementary use of antibiotic potentiators or adjuvants.20–22 Previous studies on pharmacological strategies for RecA inhibition have focused on RecA binding via the ATP binding pocket for small molecule inhibitors like suramin and congo red.23 The natural product curcumin has been recognized as a potential therapeutic agent or adjuvant24 for the treatment of an array of diseases including cancer25 and Alzheimer's disease.26,27 Curcumin has shown potential of an antibacterial agent, though relatively little is known about the molecular mechanisms at work. The compound exhibits broad-range antimicrobial activity against Gram negative bacteria including Escherichia coli, Pseudomonas aeruginosa, and Salmonella typhimurium.28,29 Curcumin also reportedly inhibited the growth of clinical isolates of Helicobacter pylori in vitro and eradicated the pathogen in a mouse model.30 However, several factors have hampered progress in research on curcumin analogues as therapeutically viable antibiotic adjuvants, which include a lack of structural information for predicting the drug binding site(s) of RecA protein, and poor pharmacokinetic/pharmacodynamic (PK/PD) properties of known compounds.24
Despite its ability to inhibit antibiotic-induced SOS response,28,29,31 curcumin reportedly did not interfere with the ATP hydrolysis required for RecA activity.23 The molecular underpinnings of how curcumin binds and inhibits RecA remain obscure, as there have been no attempts on theoretical or experimental investigation on the subject thus far. Predictions on curcumin–RecA interactions by computational approaches seem opportune in this light. It is increasingly being appreciated that rational drug design can be greatly assisted by the successful application of docking software and other allied computational approaches such as MMGBSA calculation, and MD simulation.32–35 Since the discovery and elaborate characterization of RecA protein more than a decade ago, a sizable body of works have been devoted to the development of RecA inhibitors into as antibiotic adjuvants.18,36,37 However, the absence of any RecA-based docking studies restricted the exploration of the curcumin scaffold in rational drug design.
To address the gap in our knowledge on how curcumin operates as a RecA inhibitor, we here use computational approaches including docking analysis to elucidate the possible mechanisms underlying binding between RecA protein and curcumin analogues. Our work utilized known X-ray structures of bacterial RecA proteins to make predictions on potential RecA–curcumin binding sites based on literature resources. We further predicted the key amino acid residues involved by multiple algorithms, including 3D-structure based algorithms PASS,38 ConCavity,39 POCASA,40 GHECOM,41,42 DoGSiteScore43 SiteHound.44 The binding regions were then classified into four binding pockets (pockets A, B, C and D) based on their locations on RecA and physiological functions (Fig. 1). Two groups of curcumin analogues, bis-(arylmethylidene)acetone analogues and curcumin–thalidomide hybrids, were analysed for their predicted binding affinities with respect to each of these binding pockets. Structural insights gained herein should provide a theoretical foundation for future experimental exploration including rational design of curcumin skeleton based compounds as antibiotic adjuvants to help combat RecA-mediated mutagenesis and AMR development.
Fig. 1 (A) X-ray structure of E. coli RecA with ATP and ssDNA. The structure was adopted with modifications from a reported crystal structure (PDB ID: 3CMT).13 (B) Potential binding sites of RecA inhibition predicted by POCASA (coloured spheres).40 (C) Potential binding sites of RecA inhibition predicted by PASS (red spheres).38 Prediction of potentially druggable target pockets by RecA inhibitors based on the 3D structure of E. coli RecA by using different algorithms, including (D) POCASA, (E) GHECOM, (F) ConCavity and (G) DoGSiteScore. Coloured patches represent spatial span of predicted binding pockets. |
Electrostatic potential of the protein surface (upper left of Fig. 2) offers useful clues for inferring the function of RecA protein. The loop regions L1 and L2 are marked on Fig. 2. The positively charged residues Lys248 (ref. 52) and Lys250 (blue region above L2),53,54 together with Arg243 and Lys245 (blue region of pocket C, close to L2)55 were reported to be important for the binding of RecA to dsDNA in the homologous pairing process.56 The algorithm eF-surf (electrostatic surface of functional-site) was used to calculate the molecular surface of the protein, in manners consistent with the eF-site database.50 eF-seek is a web server for the discovery of similar binding sites for uploaded protein structures.51 Each of the points above the line in the density plot (upper right of Fig. 2) corresponds to a “significant” match between the binding sites in RecA and the pockets in the eF-seek database.51 On the other hand, the points in the lower left region indicate the non-similar binding sites. Since the number of dots could be too large (about 17500) to be fully displayed, a density plot is shown instead of a scatter plot below the threshold line.
Fig. 2 Similarity search for RecA binding sites based on analysis of electrostatic potential and molecular topology of RecA. Upper left: eF-surf calculated electrostatic potential (from −0.1 V to 0.1 V) for the molecular surface of RecA protein.50 Predicted binding pockets and loop regions (L1 and L2) are displayed. Upper right: 2D density plot for the similarity search of candidate RecA binding pockets and all other binding sites. Calculations were conducted by using the eF-seek web server. Scale for the density plot is as presented on the right. Curves on the plot represent the threshold line established with the Matthews' correlation coefficient (MCC) as an evaluative measure.51 The definitions of the Z-score, coverage and score are provided in the notes of table in this figure. |
Table in Fig. 2 shows the predicted binding residues ranked by their scores. Each row in this table corresponds to a dot in the density plot (upper right of Fig. 2). Exhaustive calculations could be very time-intensive and subsequently generate hundreds of rows ranked by their score. For clarity, we selected four of these rows for discussion. Entry 1 to entry 4 represent pocket A to pocket D, respectively. The first row of this table refers to the dots highlighted with cyan in the Fig. 2 density plot, which represents the ATPase region for RecA protein. Some of the predicted key residues are also pivotal for ATPase activities, such as Glu68, Glu96, Tyr103, Gln194, etc.52,55 The predicted ligand for entry 1 in the table of Fig. 2 is ADP, in agreement with reports on RecA structures.52,55 Again, the eF-seek web server was used for our calculations.51 The clique search algorithm of this server was used for analysis of representative binding sites in the eF-site database,50 which contains about 17500 binding sites by 2007 and has been updated about twice per year since then.50 Currently, the database contains binding pockets of bacterial RecA protein, including the X-ray structure (PDB ID: 3CMT) that we applied in this study. For each query, eF-seek carried out a comparison against all binding sites in this representative ligand database.50 The similarity between the predicted binding sites on protein and each binding site in the database is evaluated by two measures, specifically, the Z-score and coverage.51 A predicted binding site with a larger Z-score and a higher coverage value would share more features similar to that of the query.
We performed parallel analysis with the algorithm SiteHound,44 whose results are as shown in Fig. 3. The “cluster data” table displays the top 6 ranking interacting energy clusters (or putative binding sites). Potential interfacial residues of RecA identified by prediction of protein interfaces are listed in the Table in Fig. 3, which describes the ranking, key residues and volume for each cluster. The sum of the energy values of all the points that belong to the same cluster or total interaction energy (TIE), which is an indication of the binding strength between RecA corresponding pockets and clusters, is used to rank the cluster. The volume of the pockets (clusters) in Å3 reflects degree of correlation with the ranking of TIE. The colouring of the clusters in Fig. 3 corresponds to their ranking number in the Table in Fig. 3. The Cartesian coordinates (x, y, z) for each centre indicate the location of each cluster. This information is useful for generating a docking box centred on a putative binding site. For example, residues Glu68, Ser69, Ser70, Gly71, Lys72, Thr73, Thr74, Leu77, Asp94, Glu96, Leu99, Asp100, Tyr103, Ala104, Asp144 of the cluster 1 in Fig. 3 is located at the ligand binding sites with the lowest energy (−1097.5 kcal mol−1) and the biggest volume (87 Å3) best predicted by SiteHound. The cluster 1 (red) and cluster 4 (light blue) are adjacent to each other. Collectively, these two clusters indicate the ATPase core (pocket A) of RecA. The key residues Glu68, Glu96, Tyr103 predicted in cluster 1 and 4 were reported to be significant for RecA ATPase activity.52 Similarly, the cluster 2 and cluster 3 are also adjacent with each other. Together, they mark the ssDNA binding region (pocket D) with Ser172, Arg176, Met197, Ile199, Thr210, Gly211, Gly212 and Asn213 as key residues. Some of these key residues are underlined in the table in Fig. 3, which means that they are also predicted by the eF-seek as key residues, as listed in table in Fig. 3.
Fig. 3 Ligand binding sites predicted by SiteHound.44 The structure displayed in the above presents a 3D view of predicted clusters (coloured spheres) in relation to the RecA protein structure. Calculations for the clusters were performed on the basis of TIE (total interacting energy) by using the Jmol Java applet. The clusters are depicted in as spheres to indicate approximate geometry. Detailed cluster data of the corresponding clusters (specified by coloured) are as shown in the above table. |
As anticipated, the enol form of curcumin tautomer 1 (enol form) is more stable than its keto counterpart tautomer 2 (keto form) in water (Fig. 4A). This result suggests that the curcumin molecule likely exists predominantly in enol form in water. This is also in agreement with the DFT computational estimation and experimental results reported by Tsonko et al.62 Based on the similarity of the scaffolds, it is reasonable to speculate that the other curcumin analogues in Schemes 1 and 2 would similarly adopt the enol form. The energy difference between the enol and keto forms is small, which means that the keto form of curcumin could nonetheless also exist during interactions with RecA.
Scheme 1 Chemical structures of curcumin analogues.65,66 |
Scheme 2 Molecular structures of the curcumin–thalidomide analogues. c21, c37 to c40 are thalidomide and thalidomide analogues, c23 to c27 are the compound 3 to 7 from ref. 73. c22 and c28 to c36 are the compounds designed in this study based on the predicted binding modes and feasibility of synthetic routes. |
In contrast to curcumin, tetrahydrocurcumin is predicted to assume the keto form in water based on DFT optimization. Tetrahydrocurcumin (Fig. 4B) is a commercially available analogue of curcumin, and could be used as a starting material for organic synthesis. It has a smaller delocalized conjugation system than curcumin, which imparts instability on the enol form of tetrahydrocurcumin. Analysis on potential energy profiles in Fig. 4 suggests that docking and subsequent MMGBSA calculations could be meaningfully pursued with the enol tautomers of compounds with curcumin skeleton and keto tautomers of compounds with tetrahydrocurcumin skeleton.
To further investigate the effect of structural modifications on binding energies, a set of reported curcumin analogues was selected to calculate the compounds' binding energies with different binding sites of RecA protein (Scheme 1 and Table 1). Two kinds of docking software were used in this study for the docking study of the curcumin analogues. The binding energies estimation results by Autodock Vina predict that this selected set of compounds preferentially bind pocket B rather than pocket D, but this observation was not supported by Ledock estimation with the same docking parameters. Molecules with a larger scaffold (c01, c02, c18, c19) seem to have higher predicted binding affinities toward pocket A and pocket B than the rest of compounds (c03–c17), though the differences are moderate. Introduction of a large group by click reaction did not result in significant higher predicted binding energies (c18, which was previously reported as GO-Y080).65 Yamakoshi and co-workers also reported that the bis-(arylmethylidene)acetone skeleton of c03–c17 could give rise to cytotoxicity effects of these compounds.65 In addition, the 3-oxo-1,4-pentadine structure (c13–c18) is essential for cytotoxicity.65 Among all these curcumin analogues, the 3-, 4-, 5-substituted compounds such as c13 and c15 showed the highest cytotoxicity.65 As c03–c17 failed to show higher predicted binding energies than curcumin or tetrahydrocurcumin, further computational analysis and rational design on lead compounds may take this finding into consideration.
Entry | Binding energies estimatedc (kcal mol−1) | |||
---|---|---|---|---|
Pocket A | Pocket B | Pocket C | Pocket D | |
a Curcumin in enol form.b Curcumin in keto form.c Binding energies outside the brackets were estimated by Autodock Vina,67 binding energies in the brackets were estimated by Ledock (http://www.lephar.com/). | ||||
c01a | −7.8 (−3.94) | −8.6 (−3.24) | −6.5 (−3.06) | −6.0 (−3.61) |
c01b | −7.2 (−3.90) | −8.0 (−3.80) | −7.6 (−3.28) | −5.7 (−3.91) |
c02 | −7.3 (−3.28) | −7.9 (−2.91) | −6.5 (−2.66) | −5.7 (−3.02) |
c03 | −6.7 (−2.89) | −7.2 (−3.04) | −6.5 (−2.71) | −5.9 (−3.02) |
c04 | −6.7 (−3.23) | −7.0 (−3.03) | −6.8 (−3.19) | −5.2 (−2.91) |
c05 | −6.5 (−3.51) | −7.4 (−3.12) | −6.9 (−3.20) | −5.3 (−2.88) |
c06 | −7.2 (−3.86) | −7.3 (−3.46) | −7.0 (−4.09) | −5.6 (−4.01) |
c07 | −6.9 (−4.14) | −7.8 (−3.79) | −7.1 (−3.86) | −5.7 (−3.90) |
c08 | −6.6 (−3.18) | −7.3 (−2.88) | −6.5 (−2.95) | −5.4 (−3.15) |
c09 | −7.0 (−4.30) | −7.6 (−4.69) | −7.0 (−4.75) | −5.9 (−4.33) |
c10 | −7.0 (−3.53) | −7.6 (−3.64) | −7.0 (−3.20) | −6.2 (−3.23) |
c11 | −6.7 (−3.11) | −7.2 (−2.63) | −6.7 (−3.12) | −5.3 (−2.99) |
c12 | −6.5 (−3.35) | −7.3 (−2.81) | −5.6 (−2.82) | −5.7 (−3.34) |
c13 | −6.9 (−3.30) | −7.1 (−3.00) | −6.5 (−2.51) | −5.4 (−3.06) |
c14 | −6.7 (−3.48) | −7.3 (−3.59) | −6.6 (−3.48) | −5.6 (−3.86) |
c15 | −6.5 (−3.25) | −7.0 (−2.31) | −5.8 (−2.68) | −5.3 (−3.21) |
c16 | −6.6 (−4.11) | −7.0 (−3.48) | −6.1 (−3.50) | −5.3 (−3.75) |
c17 | −6.9 (−2.83) | −7.3 (−2.52) | −6.2 (−2.37) | −5.3 (−2.91) |
c18 | −7.4 (−4.23) | −6.6 (−5.14) | −5.5 (−4.34) | −6.2 (−4.88) |
c19 | −7.3 (−3.96) | −7.9 (−3.37) | −7.3 (−3.44) | −6.4 (−4.73) |
c20 | −7.3 (−3.28) | −7.9 (−2.91) | −6.5 (−2.66) | −5.7 (3.02) |
Interestingly, c19 (tetrahydrocurcumin) have the highest Vina binding energy for pocket D. This is probably due to the C–C single bonds in tetrahydrocurcumin molecule (c19) allowing it to be more flexible than its curcumin counterpart (c01) and other curcumin-like molecules (c02–c18) in Table 1. However, in MMGBSA calculations, the estimated binding energies did not suggest any advantages of tetrahydrocurcumin over its curcumin counterpart. The possible binding modes for both keto and enol forms of curcumin (c01) RecA and tetrahydrocurcumin (c19) with the ssDNA binding region (pocket D) were depicted in Fig. 5. The hydroxyl group of these compounds form hydrogen bonds with the amide group of Asn213. Other key polar interactions include hydrogen bonds of these molecules with the backbone of Met197, Ala167 and/or Ala168, and with the side chain of Thr208. Given the hydrophobic features of curcumin and tetrahydrocurcumin scaffolds, it seems logical to speculate that hydrophobic interactions predominate in the binding of curcumin with bacterial RecA. Both the keto and enol forms of curcumin were predicted to make van der Waals contacts with Gly212 (Fig. 5). The enol-form and keto-form of curcumin showed similar binding potencies with the pocket D region of RecA (Table 2).
Fig. 5 Predicted binding modes of representative compounds with the ssDNA binding region (pocket D). 2D figures were generated by Poseview68,69 and refined with Chemdraw. Hydrophobic interactions are displayed as green contact curves. (A) Curcumin (c01) in enol form; (B) curcumin (c01) in keto form; (C) tetrahydrocurcumin (c19) in keto form. (D) c64 in enol form (as depicted in Scheme S1†). |
Energy termsa | RecA-inhibitor complexes | |||
---|---|---|---|---|
RecA + curcumin (enol) | RecA + curcumin (keto) | RecA + c19 | RecA + c64 | |
a Definition of the energy terms: ΔGvdW = van der Waals contribution from MM. ΔGele = EEL, electrostatic energy as calculated by the MM force field. ΔGsolv,p = EPB/EGB, which is the electrostatic contribution to the solvation free energy calculated by MMPBSA or MMGBSA respectively. ΔGsolv,np = Esurf (or Ecavity/Enpolar) for MMGBSA (MMPBSA) calculation. Nonpolar contribution to the solvation free energy. ΔGMM = ΔGele + ΔGvdW. ΔGsolv = ΔGsolv,p + ΔGsolv,np. ΔGbind = ΔGMM + ΔGsolv, final estimated binding free energy calculated from the terms above. (kcal mol−1), which is the binding free energies in the absence of entropic contribution. This is described as eqn (6) in the ESI. | ||||
ΔGvdW | −36.38 | −33.33 | −35.29 | −38.15 |
ΔGele | −22.62 | −14.27 | −19.85 | −20.11 |
ΔGsolv,p | 39.36 | 27.41 | 35.09 | 38.62 |
ΔGsolv,np | −4.94 | −4.06 | −3.67 | −4.88 |
ΔGMM | −59.00 | −47.60 | −55.14 | −58.27 |
ΔGsolv | 34.42 | 23.36 | 31.42 | 33.74 |
ΔGbind | −24.59 | −24.24 | −23.72 | −24.51 |
To further validate the binding energies, an MM-GBSA approach was adopted in re-calculation of the binding energies of several key analogues. The MM-GBSA approach was chosen for its ease and efficiency in ranking binding affinities of receptor and ligands compared with other algorithms such as MM-PSBA.33,34 In general, the binding energies calculated by the MM-GBSA approach tend to give excellent correlation with binding energies generated by experimental approaches.35
To further investigate the binding potency of the key molecules, we optimized the RecA–c01 (enol or keto form) and RecA–c19 with Amber16, and then refined the structures with a short MD simulation for the MMGBSA calculation. Detailed MMGBSA results are listed in Table 2. No significant difference was observed for RecA–curcumin (enol form, ΔGbind = −24.59 kcal mol−1) complex and RecA–curcumin (keto form, ΔGbind = −24.24 kcal mol−1) complex. Similarly, the ΔGbind of RecA–tetrahydrocurcumin and RecA–c64 (−23.72 and −24.51 kcal mol−1) did not show significant differences compared with that of the RecA–curcumin complexes. Compared with values for the RecA–curcumin enol/keto complexes, differences in the calculated binding free energies between these complexes were not significant. These energetic results suggest that ssDNA binding region of RecA (pocket D) does not have significant preference for the enol or keto tautomer of curcumin. Overall, we envision that simple modifications of the curcumin scaffold with different substitution groups (e.g. methyl, methoxyl, hydroxyl groups) would not markedly improve the predicted binding energies.
Curcumin scaffold based structural modifications in Scheme 1 do not seem to allow lower predicted energies than curcumin itself, which means that no analogues in Scheme 1 are predicted to be significantly more potent than curcumin itself (see Table 1). Furthermore, the curcumin analogues (c03–c17) with bis-(arylmethylidene)acetone skeleton may give rise to greater cytotoxicity. Since curcumin is a hydrophobic compound with calculated logP = 3.62 (https://chemaxon.com) and very low water solubility of 0.00575 mg mL−1 (https://www.drugbank.ca), introducing hydrophilic groups while keeping the scaffold of the curcumin unchanged could be a promising direction in rational drug design of curcumin-like compounds as RecA inhibitors. Thalidomide is an FDA approved drugs with higher water solubility (2.55 mg mL−1, https://www.drugbank.ca) and lower calculated logP of 0.16 (https://chemaxon.com) than curcumin. Incorporation of the thalidomide moiety as a hydrophilic group into the curcumin scaffold may help circumvent constraints during structural modification of curcumin to achieve higher binding affinity with RecA. Although thalidomide was once withdrawn due to severe teratogenicity, its safety for adults was confirmed. It has recently been reintroduced by FDA as a therapeutic agent for cancer such as human multiple myeloma and for some inflammatory diseases.72 Introduction of a thalidomide moiety into the curcumin skeleton has been attempted previously. In fact, hybrid compounds of thalidomide and curcumin (c23–c27 in Scheme 2) have been successfully designed and synthesized by Liu et al. for treating human multiple myeloma.73
Compared with the case of curcumin analogues, significantly higher binding scores (Table 1) were observed for the thalidomide–curcumin hybrids (Table 3). This applies to both of the scores generated by Autodock Vina and Ledock. Majority of these hybrid compounds are predicted to be more potent bacterial RecA inhibitors than the curcumin analogues. Interestingly, although curcumin was reportedly unable to interfere with RecA ATPase activity, which implicitly means that curcumin is not a major binder of RecA pocket A, the possibility for thalidomide-curcumin hybrids to interact with RecA pocket A cannot be ruled out.
Entry | Estimated binding energiesa (kcal mol−1) | |||
---|---|---|---|---|
Pocket A | Pocket B | Pocket C | Pocket D | |
a Binding energies outside the brackets were estimated by Autodock Vina67 and binding energies within the brackets were estimated by Ledock (http://www.lephar.com/). | ||||
c21 | −7.7 (−2.97) | −7.7 (−3.09) | −6.4 (−2.85) | −5.6 (−3.02) |
c22 | −11.5 (−5.29) | −10.5 (−6.20) | −8.6 (−5.04) | −8.3 (−4.53) |
c23 | −10.2 (−5.35) | −10.1 (−4.43) | −8.5 (−4.22) | −7.6 (−4.83) |
c24 | −9.3 (−3.98) | −9.7 (−4.36) | −7.9 (−3.83) | −8.5 (−4.61) |
c25 | −10.8 (−4.68) | −9.3 (−4.73) | −8.8 (−5.76) | −7.4 (−5.38) |
c26 | −8.9 (−4.19) | −9.4 (−3.97) | −8.0 (−4.15) | −7.4 (−4.37) |
c27 | −9.8 (−4.76) | −9.4 (−4.49) | −8.8 (−5.18) | −7.0 (−4.74) |
c28 | −11.5 (−4.94) | −10.7 (−4.80) | −9.8 (−4.39) | −8.8 (−5.57) |
c29 | −10.1 (−5.55) | −9.9 (−4.50) | −8.3 (−4.17) | −7.5 (−5.02) |
c30 | −10.0 (−5.52) | −9.4 (−6.00) | −8.1 (−6.16) | −7.5 (−6.42) |
c31 | −9.8 (−6.52) | −9.1 (−6.42) | −8.0 (−6.18) | −8.7 (−5.00) |
c32 | −9.7 (−3.93) | −11.1 (−5.69) | −7.6 (−4.11) | −8.9 (−4.89) |
c33 | −8.5 (−4.40) | −9.3 (−4.38) | −7.2 (−4.33) | −9.1 (−5.60) |
c34 | −8.8 (−4.67) | −9.6 (−5.36) | −7.7 (−4.95) | −6.7 (−5.33) |
c35 | −10.0 (−5.13) | −10.9 (−6.14) | −8.4 (−5.20) | −8.7 (−5.48) |
c36 | −9.4 (−4.24) | −9.1 (−5.15) | −7.3 (−4.51) | −6.5 (−4.27) |
c37 | −9.8 (−6.52) | −9.1 (−6.42) | −8.0 (−6.18) | −5.5 (−5.00) |
c38 | −7.3 (−2.49) | −7.9 (−2.19) | −8.1 (−2.12) | −6.1 (−2.39) |
c39 | −7.8 (−3.32) | −7.8 (−3.37) | −6.5 (−3.17) | −5.9 (−3.27) |
c40 | −7.7 (−3.21) | −7.8 (−2.96) | −7.2 (−2.95) | −5.8 (−3.14) |
The c22 and c24 are speculated to adopt the enol form as they feature a curcumin scaffold, while c32 is predicted to adopt the keto form for its tetrahydrocurcumin scaffold (Fig. 6). The binding energies (ΔGbind) of both the enol and keto forms were recalculated by MMGBSA. The free energy gap between the enol and keto forms for tetrahydrocurcumin is quite small (Fig. 4B). As shown in Table 4, the ΔGbind value of the c32 (keto form)–RecA complex (ΔGbind = −38.46 kcal mol−1) is less negative compared with that of c32 (enol form)–RecA complex (ΔGbind = −43.32 kcal mol−1), which suggests that the enol form of c32 likely binds more firmly the pocket D of RecA than does the keto form of c32. Thus, the binding process of c32 with RecA could trigger c32 to adopt an enol form.
Fig. 6 Predicted binding modes of RecA pocket D with (A) c22; (B) c24; (C) c32 in enol form; and (D) c32 in keto form. 2D figures were generated by Poseview68,69 and refined with ChemDraw. Hydrophobic interactions are displayed as green contact curves. |
Energy termsa | RecA-inhibitor complexes | ||
---|---|---|---|
RecA + c22 | RecA + c24 | RecA + c32 (enol)/c32 (keto) | |
a Definitions of the energy terms are the same as that of Table 2. | |||
ΔGvdW | −76.32 | −43.11 | −82.68/−68.72 |
ΔGele | −16.75 | −7.29 | −31.24/−1.49 |
ΔGsolv,p | 53.46 | 28.51 | 79.13/38.87 |
ΔGsolv,np | −7.37 | −5.83 | −8.54/−7.11 |
ΔGMM | −93.07 | −50.41 | −113.92/−70.21 |
ΔGsolv | 46.09 | 22.67 | 70.60/31.75 |
ΔGbind | −46.98 | −27.73 | −43.32/−38.46 |
To elaborate on our proposition that curcumin–thalidomide hybrids are more potent than other curcumin-like compounds, the binding energies of 20 curcumin building blocks (compounds c41–c60, in Scheme S1†) and 25 additional curcumin analogues (compounds c61–c85, in Scheme S2†) were further predicted (see structural details in the ESI, Pages S13–S15†). As shown in Table S3,† the additional curcumin analogues in Scheme S2† consistently showed significantly larger predicted binding energies (e.g. energies range from −5.6 to −6.4 for pocket D) than that of building blocks in Scheme S1† (e.g. energies range from −4.3 to −5.2 for pocket D). Therefore, the additional curcumin analogues in Scheme S2† are predicted to be more potent RecA inhibitors than the building blocks in the Scheme S1.† However, none of the compounds from these two groups are predicted to be more potent than the thalidomide–curcumin hybrids (e.g. energies range from −6.5 to −9.1 for pocket D), as shown in Table 3.
The above results indicate that the curcumin–thalidomide hybrids in Scheme 2 could shed light on new directions in the rational design of novel curcumin analogues as bacterial RecA inhibitors for blocking the bacterial SOS pathway. Sources of the 85 compounds investigated in this study are as listed in Table 5.
Entry | Compounds | Classification | Applications | Ref. |
---|---|---|---|---|
1 | c01–c20 | Curcumin and curcumin analogues | Inhibitors of bacterial RecA protein; cancer treatment | 65 and 66 |
2 | c23–c27 | Curcumin–thalidomide conjugates | Treatment of multiple myeloma | 73 |
3 | c22, c28–c37 | Rational drug design of this study | Predicted RecA protein inhibitors | None |
4 | c21, c38–c40 | Thalidomide and its analogues | “Building blocks” for rational design | None |
5 | c41–c55 | Reported curcumin “building blocks” | Creating antimicrobial food-contact surfaces | 74 |
6 | c56–c85 | Additional curcumin analogues | Inhibitors of bacterial sialidase | 75 and 76 |
Footnotes |
† Electronic supplementary information (ESI) available. See DOI: 10.1039/c9ra00064j |
‡ These authors contributed equally to this work. |
This journal is © The Royal Society of Chemistry 2019 |